AbCellera (ABCL) Is Up 18.8% After Pivoting To Clinical Stage And Filing Share Offering

• AbCellera Biologics Inc. has reported its full-year 2025 results, with revenue rising to US$75.13 million and net loss easing to US$146.41 million, while also filing a US$45.54 million shelf registration for 15,030,034 common shares tied to an employee share offering.
• Alongside these financials, AbCellera’s shift into a clinical-stage biotech with advancing programs ABCL635 and ABCL575 and a nearly completed manufacturing facility signals a business model increasingly centered on internal drug development and clinical execution.
• With AbCellera now operating as a clinical-stage biotech, we’ll examine how this pipeline progress reshapes its investment narrative and risk profile.

Find 46 companies with promising cash flow potential yet trading below their fair value.

AbCellera Biologics Investment Narrative Recap

To own AbCellera, you need to believe its shift from a fee-for-service platform to a clinical-stage biotech can eventually justify today’s losses and rich sales multiple. The latest results, a higher full-year 2025 revenue of US$75.13 million and narrower net loss of US$146.41 million, do not materially change the key near term catalyst, the ABCL635 Phase 1/2 readout in Q3 2026, or the biggest risk, that clinical data fail to support commercial potential.

The most relevant update here is AbCellera’s US$45.54 million shelf registration for 15,030,034 common shares under its employee share offering. While this filing does not directly affect the ABCL635 or ABCL575 timelines, it matters in the context of a company that remains unprofitable, is increasing reliance on internal programs, and may see more volatile, back loaded revenue streams as it shifts away from partner research fees toward milestones and royalties.

Yet even as the story shifts to long term upside, investors should be aware that heavy R&D spending and uncertain clinical outcomes could still...

Read the full narrative on AbCellera Biologics (it's free!)

AbCellera Biologics' narrative projects $123.3 million revenue and $17.5 million earnings by 2028. This requires 55.4% yearly revenue growth and a $183.2 million earnings increase from $-165.7 million today.

Uncover how AbCellera Biologics' forecasts yield a $9.83 fair value, a 172% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming revenue could climb toward about US$250 million by 2028, which is far more upbeat than the baseline view and could be revised meaningfully as AbCellera’s clinical data, cash use, and manufacturing plans evolve from here.

Explore 9 other fair value estimates on AbCellera Biologics - why the stock might be worth just $7.00!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your AbCellera Biologics research is our analysis highlighting 3 important warning signs that could impact your investment decision.
• Our free AbCellera Biologics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AbCellera Biologics' overall financial health at a glance.

Seeking Other Investments?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com